Eukaryotic gene transcription is influenced by chromatin modifications that are under the control of epigenetic regulatory proteins. In addition to genetic alterations, it is now apparent that epigenetic mechanisms are also central to cancer pathogenesis. Epigenetic alterations are heritable, drive neoplastic progression, and undergo the same selective pressure as genetic alterations. Therefore identifying the key epigenetic regulators in cancers should point to new and better therapeutic approaches. An integrative biology approach has been employed to identify and dissect the role that families of histone modifying enzymes play in the development of pancreatic ductal adenocarcinoma (PDAC), the 4th most common cause of cancer death in the United States. This unbiased genetic screen led the discovery of the family of jumonji-domain histone demethylases (HDMs) as important regulators of PDAC. In particular, it has been found that the HDM, KDM2B, was highly upregulated in PDAC and was required for the tumorigenicity of PDAC cell lines and the immortalization and transformation of primary cells. By using gain- and loss-of-function approaches and genetically engineered mouse models we propose to delineate the molecular mechanisms by which KDM2B contributes to PDAC initiation, progression, and maintenance by defining key target genes and establishing the functional interaction between KDM2B and other chromatin modifying enzymes. Given the reversibility of histone methylation and the importance of the Jumonji domain, KDM2B -unlike many other oncogenic transcriptional regulators- represents an attractive candidate for the development of small molecule inhibitors.

Public Health Relevance

In addition to genetic alterations, epigenetic mechanisms are also central to cancer pathogenesis. Epigenetic alterations are heritable, drive neoplastic progression, and undergo the same selective pressure as genetic alterations. Identifying the key epigenetic regulators in cancer should point to new and better therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Transition Award (R00)
Project #
5R00CA158582-04
Application #
8850822
Study Section
Special Emphasis Panel (NSS)
Program Officer
Okano, Paul
Project Start
2014-05-20
Project End
2017-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
George Washington University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
043990498
City
Washington
State
DC
Country
United States
Zip Code
20052
Andricovich, Jaclyn; Perkail, Stephanie; Kai, Yan et al. (2018) Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 33:512-526.e8
Kai, Yan; Andricovich, Jaclyn; Zeng, Zhouhao et al. (2018) Predicting CTCF-mediated chromatin interactions by integrating genomic and epigenomic features. Nat Commun 9:4221
Chen, Jian; Shukla, Vivek; Farci, Patrizia et al. (2017) Loss of the transforming growth factor-? effector ?2-Spectrin promotes genomic instability. Hepatology 65:678-693
Andricovich, Jaclyn; Kai, Yan; Tzatsos, Alexandros (2016) Lysine-specific histone demethylases in normal and malignant hematopoiesis. Exp Hematol 44:778-82
Chen, Jian; Katz, Lior H; Muñoz, Nina M et al. (2016) Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-?/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. Sci Rep 6:30217
Andricovich, Jaclyn; Kai, Yan; Peng, Weiqun et al. (2016) Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis. J Clin Invest 126:905-20
Papageorgis, Panagiotis; Ozturk, Sait; Lambert, Arthur W et al. (2015) Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res 17:98